On April 9, 2026, AITRICS obtained medical device approval for AITRICS-VC (VitalCare) in Indonesia, securing regulatory approvals in five markets including the U.S. (FDA pending), Vietnam, Hong Kong, and South Korea. On April 28, 2026, the company signed an MOU with the Department of Health of Hung Yen Province, Vietnam to strengthen digital healthcare infrastructure. On April 16, 2026, AITRICS announced an AI Ethics Checklist developed in collaboration with clinical partners. In February 2026, three research papers were accepted at ICLR 2026. In March 2026, the company was selected for South Korea's 2026 AI Voucher Support Program and showcased its full product lineup at KIMES 2026 to mark its 10th anniversary.
Company Profile (Updated April 2026)
AITRICS（에이아이트릭스） is a leADINg South Korean medical AI company focused on developing clinical decision support systems (CDSS) that leverage predictive analytics to improve patient outcomes and clinical workflow efficiency. Headquartered in Gangnam-gu, Seoul, South Korea, the company was founded in 2016 by Dr. Kwang-Joon Kim, a practicing physician who established the company to address critical unmet needs he personally experienced in clinical settings. AITRICS combines advanced mACHine learning, explainAble AI (XAI), and natural language processing to deliver real-time patient monitoring and AI-assisted clinical tools.
Development History:
- 2016: AITRICS founded in Seoul, South Korea, by CEO Dr. Kwang-Joon Kim
- 2019: Completed Series A funding; began large-scale national R＆D project with UNIST, KAIST, Korea University, and Yonsei Hospital, backed by 15 billion won from the Ministry of Science and ICT to develop explainable AI technology
- 2020: Initiated partnership with Cleveland Clinic to validate VitalCare's predictive performance using the hospital system's clinical database
- 2021: Raised 3.5 billion won in Pre-Series B funding; began expanding professional workforce for medical AI research
- 2022: AITRICS-VC (VitalCare) received approval from the Korean Ministry of Food and Drug Safety (MFDS) on October 26 as an AI monitoring solution for predicting death, ICU transfer, cardiac arrest, and sepsis; recognized as an innovative medical device manufacturer by MFDS
- 2023: Established U.S. entity in December to prepare for North American market entry; VitalCare recognized as a non-reimbursable item and supplied to domestic hospitals from March 2023
- 2024: Raised 27.1 billion won ($20.1 million) in Series B funding; submitted U.S. FDA 510(k) application in August for VitalCare; revenue reached approximately 9.5 billion won ($6.7 million); obtained Vietnam medical device approval in October 2024
- 2025: Established Japanese subsidiary in Tokyo (March); received Hong Kong Medical Device Division clearance (May); signed Mayo Clinic Platform partnership (September); granted MFDS Innovative Medical Device Manufacturer certification with Rapid commercialization support; selected as KODIT Innovation Icon (November), securing up to 20 billion won in credit guarantees over three years; closed Series C funding of 35 billion won ($24 million) (November–December); received New Excellent Technology (NET) certification from Ministry of Health and Welfare
- 2026: Selected for 2026 AI Voucher Support Program (March); exhibited at KIMES 2026 celebrating 10th anniversary (March); three papers accepted at ICLR 2026 (February); selected as 2026 Emerging AI+X Top 100 company in Healthcare category (January); obtained Indonesia medical device approval (April 9); signed MOU with Vietnam Hung Yen Provincial Health Department (April 28); published AI Ethics Checklist (April 16); actively preparing U.S. clinical trials of VitalCare and expanding across Asia
Core Mission: To transform healthcare delivery by providing AI-powered predictive insights that enable clinicians to intervene before patient deterioration occurs, thereby reducing mortality, optimizing medical resource allocation, and enhancing patient safety across intensive care units and general wards.
Core Products ＆ Technology Platform
AITRICS-VC (VitalCare) - Patient Deterioration Prediction
VitalCare is AITRICS' flagship AI-powered clinical decision support software designed for real-time prediction of patient deterioration in both intensive care units (ICU) and general wards. The system continuously analyzes 19 types of EMR data, including six vital signs, 11 blood test results, patient consciousness status, and age, to generate early warnings.
Prediction Capabilities:
- ICU: Death within 6 hours, sepsis within 4 hours, acute severe events (death, ICU transfer, cardiac arrest)
- General Ward: Death within 6 hours, unexpected ICU transfer, cardiac arrest, sepsis within 4 hours
- Cardiac Arrest: Prediction within 24 hours
Clinical Performance (MFDS Trial Results):
- ICU acute severe events prediction AUROC: 0.96
- Sepsis prediction AUROC: 0.87
- ICU mortality prediction AUROC: 0.98
- First and only software in Korea to prove predictive performance for sepsis, death, and unexpected ICU transfer in general wards
- Reduced hospital code blue occurrence by approximately 25% according to published research
Key Features:
- Real-time EMR data integration with existing hospital systems (including ezCaretech EHR)
- Explainable AI (XAI) that provides reasoning behind predictions to support clinical decision-making
- Automated early warning scores and risk stratification
- Deployed in approximately 150+ medical institutions across South Korea and Japan
V.Doc Pro - AI Clinician Copilot
V.Doc Pro is AITRICS' next-generation AI copilot solution designed to streamline clinical workflows and optimize medical protocols. It is powered by AITRICS' proprietary medical large language model MOCA (Medical Orchestration Cooperative Agents) and supports the entire patient consultation lifecycle.
Core Functions:
- Generates AI-based pre-consultation questionnaires tailored to each patient
- Organizes and structures clinical data before physician meetings
- Records and summarizes consultations in real time using speech-to-text (STT) technology
- Automatically generates post-care instructions to support patient health management
- Customizable solutions for each medical institution's specific protocols
V.Doc - Telemedicine Enhancement
An earlier-generation solution focused on enhancing the accuracy and efficiency of telemedicine consultations, serving as a Foundation for the development of V.Doc Pro.
VitalCare 2.0 - Next Generation Platform
AITRICS is actively developing VitalCare 2.0, a next-generation platform enhanced with advanced explainable AI (XAI) capabilities to further improve prediction accuracy and clinical USAbility across broader care settings.
Regulatory Approvals ＆ Compliance
Approved Markets
- South Korea (MFDS): Approved October 2022 for VitalCare as AI monitoring software; certified as Innovative Medical Device Manufacturer in 2025
- Vietnam (Ministry of Health): Approved October 2024 — first Southeast Asian market entry
- Hong Kong (Medical Device Division): Approved May 2025 — fourth regulatory approval overall
- Indonesia (Ministry of Health): Approved April 9, 2026 — fifth market approval, accelerating Southeast Asian expansion
- United States (FDA): 510(k) application submitted August 2024, currently pending clearance; planned U.S. clinical trials underway in collaboration with Mayo Clinic Platform
- Japan (PMDA): Approval process ongoing following establishment of Tokyo subsidiary in March 2025
Financial Performance ＆ Funding History
Revenue Metrics
- 2024 Revenue: Approximately 9.5 billion won ($6.7 million)
- 2025 Projected Revenue: On track to exceed 20 billion won ($14.1 million), driven by non-reimbursable market entry and hospital adoption growth
- Company Stage: Generating Revenue (Series C)
Funding Rounds (Cumulative ~$51 Million)
- Seed ＆ Series A (2017, 2019): ~7.5 billion won (~$5.1 million)
- Pre-Series B (2021): 3.5 billion won (~$2.6 million)
- Series B (2024): 27.1 billion won (~$20.1 million) — investors Included Premier Partners, BNH Investment, BSK Investment, Bonum Investment, DS Investment ＆ Securities, Ulmers Investment, HB Investment, Shinyoung Securities, HRZ
- Series C (Nov–Dec 2025): 35 billion won (~$24 million) — led by Premier Partners, Hanriver Partners, Mirae Asset Venture Investment, Shinhan/BSK Investment, with new participation from KB Securities–Solidus Investment, SV Investment, and Mirae Asset Capital
- Total Raised: Approximately 73.1 billion won ($51 million)
Government ＆ Institutional Support
- Selected as 14th KODIT Innovation Icon (November 2025), securing up to 20 billion won in credit guarantees over three years at the lowest guarantee fee rate (0.5%)
- Received New Excellent Technology (NET) certification from South Korea's Ministry of Health and Welfare (2025)
- Selected for 2026 AI Voucher Support Program (March 2026) led by Ministry of Science and ICT and NIPA
- Selected as 2026 Emerging AI+X Top 100 company in Healthcare category (January 2026)
Company Overview
Corporate Information
Company Name: AITRICS Co., Ltd.（에이아이트릭스）
Founded: 2016
Headquarters: 218, Teheran-ro, Gangnam-gu, 13F, Seoul, 06627, South Korea
Phone: +82-2-569-5507
Company Type: Private Venture-Backed Company
Industry: Medical AI / Clinical Decision Support Software (SaMD)
CEO ＆ Founder: Dr. Kwang-Joon Kim (practicing physician)
Global Subsidiaries ＆ Entities
- Japan: Tokyo subsidiary established March 2025 (Chuo-ku, Tokyo)
- United States: U.S. entity established December 2023; collaboration with Mayo Clinic Platform and Cleveland Clinic
Strategic Partnerships ＆ Collaborations
Global Partners
- Mayo Clinic Platform (USA): Strategic partnership signed September 2025 for joint development, validation, and commercialization of advanced AI models; includes access to clinical data, IP rights, and U.S. distribution pathways; foundation for FDA clearance and U.S. market entry
- Cleveland Clinic (USA): Research partnership since 2020 to validate VitalCare's performance and improve accuracy of patient deterioration detection using Cleveland Clinic's clinical database
- Philips Korea: Collaboration to develop AI-based CDSS solutions for intensive care units to improve patient survival rates
Domestic Medical Institutions
- Asan Medical Center: Research partnership for diagnostic technology development and clinical testing of VitalCare
- Severance Hospital / Yonsei University: Collaboration in VitalCare development; Professor Kyung-soo Jeong participated in clinical validation
- Korea University Anam Hospital: Joint research agreement (2024) for research publication and medical service improvement
- Chung-Ang University Hospital: Joint research agreement (2024)
- Eunseong Medical Foundation / Good Hospitals: Active deployment of VitalCare
- Gangnam Severance Hospital: Early adopter of VitalCare
Technology ＆ Distribution Partners
- ezCaretech: Integration of VitalCare into one of South Korea's popular EHR systems
- JETRO (Japan External Trade Organization): Supported AITRICS' Japan market entry through expert meetings and collaborative development facilitation
Global Market ＆ Competitive Landscape
Target Markets (2026 Strategy)
United States: Priority market pending FDA 510(k) clearance; U.S. clinical trials planned through Mayo Clinic Platform collaboration; targeting ICU and general ward deployment
Japan: Tokyo subsidiary operational; PMDA approval in process; partnerships with Japanese healthcare firms expected
Southeast Asia: Vietnam approval secured (October 2024) as bridgehead; MOU signed with Hung Yen Province (April 2026); Indonesia approval secured (April 2026); regulatory applications prepared for Malaysia and other markets; Hong Kong approval secured (May 2025)
South Korea: Core market with 150+ medical institutions; expanded adoption through AI Voucher Program and public hospital integration
Primary Competitors
- Viz.ai (USA): AI-powered care coordination and disease detection
- Clew Medical (USA): AI predictive analytics for ICU capacity expansion
- AgileMD (USA): Clinical decision support and EHR integration
- VUNO (South Korea): Medical AI company with cardiac arrest risk assessment tools
- Cytovale (USA): Sepsis early detection diagnostics
Competitive Advantages
- First-Mover in Korea: First and only MFDS-approved software to prove predictive performance for sepsis, death, and unexpected ICU transfer in general wards
- Superior Clinical Accuracy: AUROC scores of 0.96 (acute severe events), 0.98 (mortality), and 0.87 (sepsis) based on rigorous clinical trials
- Explainable AI (XAI): Proprietary technology that explains the reasoning behind AI predictions, increasing clinician trust and adoption
- Global Tier-1 Partnerships: Collaborations with Mayo Clinic and Cleveland Clinic provide clinical validation and U.S. market credibility
- Multi-Modal Platform: Comprehensive portfolio spanning deterioration prediction (VitalCare), clinician copilot (V.Doc Pro powered by MOCA LLM), and telemedicine (V.Doc)
- Regulatory Momentum: Five international approvals/entries (Korea, Vietnam, Hong Kong, Indonesia, FDA pending) demonstrating global compliance capability
- Proven Clinical Impact: Documented ~25% reduction in code blue rates and 10–20% increase in patient throughput at adopting hospitals
2026 Outlook ＆ Strategic Priorities
Near-Term Objectives
- U.S. FDA Clearance: Secure 510(k) approval for VitalCare and launch U.S. clinical trials through Mayo Clinic Platform collaboration
- Southeast Asian Market Expansion: Execute commercial launches in Vietnam, Indonesia, and Hong Kong; advance regulatory applications in Malaysia and other markets
- Japan Market Entry: Obtain PMDA approval and establish partnerships with Japanese hospitals and medical device distributors
- V.Doc Pro Commercialization: Scale deployment through South Korea's AI Voucher Support Program and expand to international markets
- VitalCare 2.0 Development: Advance next-generation XAI-enhanced platform for broader care settings
- Revenue Growth: Target sustained revenue acceleration beyond 20 billion won annually through diversified product adoption
Contact Information
Corporate Headquarters
Address: 218, Teheran-ro, Gangnam-gu, 13F, Seoul, 06627, South Korea
Phone: +82-2-569-5507
Global Offices
Japan Subsidiary: Chuo-ku, Tokyo, Japan (Established March 2025)
U.S. Entity: Established December 2023
Online Presence
Corporate Website: www.aitrics.com
Korean Website: aitrics.com/kr/
English Website: aitrics.com/en/
Keywords: AITRICS,에이아이트릭스,VitalCare,AITRICS-VC,V.Doc Pro,MOCA,medical AI,clinical decision support,CDSS,patient deterioration,sepsis prediction,cardiac arrest prediction,ICU transfer,EMR,healthcare AI,Kwang-Joon Kim,Seoul,South Korea,Mayo Clinic,Cleveland Clinic,Philips,MFDS,FDA 510(k),Vietnam,Hong Kong,Indonesia,Japan,Tokyo,PMDA,explainable AI,XAI,predictive analytics,AUROC,AI Voucher,Innovation Icon,KODIT,NET certification,ezCaretech,JETRO,Series C,venture capital,Gangnam,KIMES 2026,ICLR 2026,VitalCare 2.0,code blue,Hung Yen
